Expert: Human monoclonal antibody targeting extracellular alpha-synuclein in all major forms. Prevents neuronal uptake and inhibits seeding of aggregation. Active Fc region facilitates immune-mediated clearance via microglial phagocytosis.

Everyday: Targets and clears a toxic protein (alpha-synuclein) that clumps together in the brain and kills nerve cells. Like a cleanup crew removing the garbage that is clogging and damaging brain cells.

Targets: []

First-in-class anti-alpha-synuclein mAb for Multiple System Atrophy. Developed by Lundbeck using Genmab technology. FDA Fast Track designation. Phase 3 MASCOT trial (NCT06706622) initiated 2025. If successful, would be first approved treatment for MSA — a rare disease with zero approved therapies.